Search results
Showing 7441 to 7455 of 8314 results
Interventional procedures, IPG454 - Issued: April 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 603.
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG447)
Interventional procedures, IPG447 - Issued: March 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 478.
Sutureless aortic valve replacement for aortic stenosis (IPG456)
Interventional procedures, IPG456 - Issued: July 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 624.
Interventional procedures, IPG479 - Issued: February 2014 --> This guidance has been updated and replaced by NICE interventional procedures guidance 631.
Insertion of endobronchial valves for lung volume reduction in emphysema (IPG465)
Interventional procedures, IPG465 - Issued: September 2013 --> This guidance has been updated and replaced by NICE interventional procedures guidance 600.
Interventional procedures, IPG51 - Issued: March 2004 --> This guidance has been withdrawn as the use of this procedure is now covered in the NICE guideline on heavy menstrual bleeding: assessment and management. NICE has no plans to carry out further assessment of this procedure under the Interventional Procedures Programme.
Transcatheter valve-in-valve implantation for aortic bioprosthetic valve dysfunction (IPG504)
Interventional procedures, IPG504 - Issued: September 2014 --> This guidance has been updated and replaced by NICE interventional procedures guidance 653.
Endovascular aneurysm sealing for abdominal aortic aneurysm (IPG547)
March 2019: We have withdrawn the guidance because the CE mark for the Nellix Endovascular Aneurysm Sealing (EVAS) System has been withdrawn. Endologix is recalling unused stock. The MHRA recommends enhanced patient surveillance (see MDA/2019/002) because of a high risk of the graft failing beyond 2 years after implantation.
This guidance has been updated and replaced by NICE interventional procedures guidance 796.
Hysteroscopic sterilisation by insertion of intrafallopian implants (IPG587)
October 2017: The device used in this procedure (Essure) no longer has a CE mark. The CE mark is necessary for medical devices to be used in EU countries. Therefore NICE has decided to suspend its guidance. NICE would consider whether to issue new guidance on “Hysteroscopic sterilisation by insertion of intrafallopian implants” should evidence including an appropriately CE marked device become available.
This guidance has been updated and replaced by NICE interventional procedures guidance 762.
This guidance has been updated and replaced by NICE interventional procedures guidance 794.
This guidance has been updated and replaced by NICE interventional procedures guidance 802.
October 2018: The device used in this procedure (CyPass) has been withdrawn by the manufacturer Alcon, because of concerns about its long-term safety. Further details can be found in the Voluntary Field Safety Notice issued by Alcon. Surgeons are advised not to implant this device, to return any unused devices to Alcon and to consider reviewing any patients who have already been implanted with CyPass. Therefore NICE has decided to withdraw its guidance. NICE would consider whether to issue new guidance on ab interno supraciliary microstent insertion with phacoemulsification for primary open-angle glaucoma should evidence using an appropriately CE marked device become available.
Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife (IPG85)
Interventional procedures, IPG85 - Issued: August 2004 --> This guidance has been updated and replaced by NICE interventional procedures guidance 715.